Prieto Introduces World’s Fastest-Charging Battery That Charges in 3 Minutes
22.5.2023 16:03:00 EEST | Business Wire | Press release
Prieto Battery, Inc., a world leader in advanced lithium-ion battery technology, unveiled the most recent prototype of its patented 3D interdigitated battery that delivers groundbreaking performance:
- 3-minute hyper-fast charge
- Operates and charges in extremely low (-30 degrees C) and high (+100 degrees C) temperatures
- Nonflammable
All three attributes of Prieto’s lithium-ion battery were tested and validated by a third-party accredited battery testing lab.
Hyper-Fast Charge
“Prieto’s battery will charge faster than you can fill your car’s gas tank,” said Mike Rosenberg, Prieto CEO. “When you charge your car faster than gassing up, range is no longer a hindrance and everyone becomes a potential EV buyer.”
Due to its 3D architecture, Prieto’s battery fully charges in three minutes and achieves a 50% charge in 90 seconds, regardless of size.
“A three-minute charge fundamentally changes how companies can design their products and how consumers use them,” added Rosenberg.
All-Weather Extreme Temperature Operation
The Prieto 3D battery delivers the industry’s widest temperature operation. Not only does it operate at -30 degrees C (-22 degrees F), but it also charges at that temperature. The battery also operates and is safe at temperatures as high as +100 degrees C (212 degrees F).
“Prieto’s battery is the only battery that we are aware of that will not only operate, but will also charge at -30 degrees Celsius,” explained Rosenberg. “As we learned this past winter when extreme cold weather hit North America, many people were left stranded with dead EVs. Our battery would have allowed these EVs to continue to operate and charge, instilling confidence in drivers to rely on their EVs even in extreme temperatures.”
Nonflammable
Prieto’s 3D architecture and design ensure that the battery is not flammable or combustible. A third-party lab conducted the gold standard “nail penetration test” on Prieto’s battery that resulted in no fire or explosion, and the battery continued to operate.
“Prieto’s battery operates safely and will not catch fire like traditional lithium-ion batteries,” Rosenberg said. “The 3D architecture and the materials we use ensure that our batteries will not experience thermal runaways or fires, which gives consumers peace of mind.”
3D Interdigitated Technology
“Our founder, Dr. Amy Prieto, reimagined the entire architecture of a conventional battery and developed the first 3D interdigitated battery,” said Rosenberg. “We’re introducing a better architecture and a better process, which results in a better battery and a superior consumer experience. This is truly the next evolution that will redefine the way we power our lives.”
Prieto’s 3D architecture is completely different from all other batteries. Today’s batteries use a decades-old 2D architecture that must always compromise between energy storage and fast charging. In 2D batteries, energy can only flow in one direction across a two-dimensional plane. To charge, lithium ions must flow from one surface to the other, resulting in serious limitations. Thicker 2D batteries store more energy, but the long ion pathways result in slow charging. Thinner 2D batteries can charge faster but cannot store much energy.
“We’ve dramatically shortened the diffusion length in any direction, which takes charging to hyper-speed and delivers more power and energy storage than 2D batteries,” said Dr. Prieto, founder and chief technology officer of Prieto. “The core of our battery looks like a thin copper sponge, and the ions only have to travel from one strand to the next, a fraction of the distance in traditional 2D batteries.”
Prieto’s battery is designed to deliver five times the power density (20C discharge rate) and up to three times the energy density of conventional 2D batteries. It is customizable to any size or application, making it ideal for anything from electric vehicles to power tools, medical devices to mobile phones and small home appliances.
Simple, Cost-Effective Manufacturing
Prieto’s new battery boasts a unique manufacturing advantage because it is made from low-cost, sustainable materials with a simple and scalable process. Prieto uses a proven water-based electroplating process at room temperature and its process requires no dry rooms, clean rooms, or other expensive equipment.
“From day one I prioritized manufacturing ahead of the battery design, and I knew to reimagine the battery we would first have to simplify production to scale up quickly, efficiently, and affordably,” said Dr. Prieto.
Prieto’s current laboratory manufacturing yield rates are more than 90%.
“We now turn our focus to commercialization as we finalize plans to build our pilot manufacturing facility,” said Rosenberg. “Our high yield rates, combined with our simple and familiar manufacturing process used in many other industries, will ultimately result in much lower costs than traditional lithium-ion batteries and gives us a great degree of confidence.”
Prieto is currently in discussions for manufacturing and applications with potential partners.
About Prieto
Prieto developed a proprietary 3D interdigitated lithium-ion battery that delivers transformational performance, such as hyper-fast charging, wide temperature operations and is safe, at a competitive cost. Its battery is customizable to all shapes and sizes for use in electric vehicles, consumer electronics and commercial equipment. Prieto also patented a unique electroplating manufacturing process that uses non-toxic materials without the need for highly specialized facilities. The company was founded in 2009. Prieto’s lab and headquarters are in Fort Collins, Colorado. Visit prietobattery.com.
About Dr. Amy Prieto
Dr. Prieto is the founder and chief technology officer at Prieto. She earned her doctorate in Chemistry from the University of California, Berkeley, and completed her postdoctoral work at Harvard University. She received the Presidential Early Career Award for Scientists and Engineers for this battery technology and is recognized by the Smithsonian Institution, where her innovation is on display in its museum in Washington, D.C.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005396/en/
Contact information
Lisa Metzger
lisametzger@avocetcommunications.com
John Hall
john@avocetcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
